Subdirección de Investigaciones Clínicas, Laboratorio de Neurofarmacología Conductual, Microcirugía y Terapéutica Experimental, Instituto Nacional de Psiquiatría, Ciudad de México, México.
Behav Pharmacol. 2023 Sep 1;34(6):362-374. doi: 10.1097/FBP.0000000000000743. Epub 2023 Aug 2.
Epidemiological studies have mentioned that cocaine use disorder (CUD) has increased in the last decade among women; these show endocrine and reproductive disorders and a high propensity to stress and depression disorders. Mirtazapine-a tetracyclic antidepressant-decreases cocaine-induced locomotor activity and locomotor sensitization in male rats. The objective of this study was to evaluate if estradiol alters the efficacy of mirtazapine to decrease cocaine-induced locomotor activity in sham and ovariectomized female rats. Three hundred and twenty adult female Wistar rats were assigned to three experimental protocols. For experiments, 1-3, female rats were daily dosed with 10 mg/kg of cocaine during the 10 days of induction and expression of locomotor sensitization. During drug withdrawal (30 days), cocaine was withdrawn and the groups received daily mirtazapine, estradiol, or saline. In addition, the females underwent sham or ovariectomy surgery. Tamoxifen was administered during the antagonism phase. After each administration, locomotor activity for each animal was recorded for 30 min in activity chambers. The dosage of mirtazapine reduces estradiol-induced enhancement in cocaine-dependent locomotor activity during the expression of locomotor sensitization in sham and ovariectomized female rats. As well as they showed that estradiol co-dosed with mirtazapine enhances the efficacy of mirtazapine to decrease cocaine-induced locomotor activity. Finally, tamoxifen enhanced the estradiol and mirtazapine-induced decrease in the cocaine motor effect in female rats. Mirtazapine may be considered an effective therapeutic option for the treatment of CUD in women, even in those who are on hormonal treatment or antidepressant therapy with estradiol.
流行病学研究提到,在过去十年中,女性可卡因使用障碍(CUD)有所增加;这些表现为内分泌和生殖紊乱,以及高度倾向于应激和抑郁障碍。米氮平 - 一种四环抗抑郁药 - 可降低雄性大鼠可卡因诱导的运动活动和运动敏化。本研究的目的是评估雌二醇是否改变米氮平降低假手术和卵巢切除雌性大鼠可卡因诱导的运动活动的功效。三百二十只成年雌性 Wistar 大鼠被分配到三个实验方案中。在实验 1-3 中,雌性大鼠在诱导和表达运动敏化的 10 天内每天接受 10mg/kg 的可卡因给药。在药物戒断期间(30 天),停用可卡因,各组每天接受米氮平、雌二醇或生理盐水。此外,女性接受假手术或卵巢切除术。在拮抗阶段给予他莫昔芬。每次给药后,将每个动物的运动活动记录在活动室中 30 分钟。米氮平的剂量可降低在假手术和卵巢切除雌性大鼠中表达运动敏化期间雌二醇诱导的可卡因依赖运动活动的增强。并且它们表明,雌二醇与米氮平共同给药可增强米氮平降低可卡因诱导的运动活动的功效。最后,他莫昔芬增强了雌二醇和米氮平诱导的可卡因运动效应的降低在雌性大鼠中。米氮平可被认为是治疗女性 CUD 的有效治疗选择,即使是那些正在接受激素治疗或雌激素抗抑郁治疗的女性。